Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:12:43.698Z.
Consensus retrieved: 2026-10-06T12:58:55.181Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:12:43.698Z.
Quote observation: 2026-10-06T15:10:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fc2e94c8beea8e322b310e9b25a1b89028fd55b2fc6a2790cf1d230843e32158
FORWARD PE RATIO
N/A
Incannex Healthcare Limited
Market Cap
$38.03M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Incannex Healthcare Limited (IXHL) | $38.03M | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.57M | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.52M | N/A |
| DocGo Inc. (DCGO)vs › | $36.48M | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.25M | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.09M | N/A |
| Nephros, Inc. (NEPH)vs › | $40.17M | 23.62 |
| Elutia Inc (ELUT)vs › | $35.36M | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.89M | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $41.71M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-06-30
Consensus estimates for this stock are reported in USD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
